Bromine → 4-[5-Bromo-4-(2-phenylethyl)-1,3-thiazol-2-yl]piperidine

HRID 549949Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 549949
[Br:1]Br.Cl.[C:4]1([CH2:10][CH2:11][C:12]2[N:13]=[C:14]([CH:17]3[CH2:22][CH2:21][NH:20][CH2:19][CH2:18]3)[S:15][CH:16]=2)[CH:9]=[CH:8][CH:7]=[CH:6][CH:5]=1.C(=O)(O)[O-].[Na+]>C(O)(=O)C>[Br:1][C:16]1[S:15][C:14]([CH:17]2[CH2:22][CH2:21][NH:20][CH2:19][CH2:18]2)=[N:13][C:12]=1[CH2:11][CH2:10][C:4]1[CH:9]=[CH:8][CH:7]=[CH:6][CH:5]=1

Komponenten

5

Edukt 3

HCID 24408BromineHCID 516892Sodium BicarbonateHCID 671568834-[4-(2-Phenylethyl)-1,3-thiazol-2-yl]piperidine hydrochloride

Produkt 1

HCID 671568564-[5-Bromo-4-(2-phenylethyl)-1,3-thiazol-2-yl]piperidine

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 176Acetic AcidLösungsmittel

Versuchsvorschrift

At 0° C., bromine (123 mg) is added dropwise to a solution of 4-[4-(2-phenylethyl)-1,3-thiazol-2-yl]piperidine hydrochloride (II-1, 200 mg) in acetic acid (2 ml). The mixture is stirred for 30 min, and saturated sodium bicarbonate solution is then added. The aqueous phase is separated off and extracted with ethyl acetate. The combined organic phases are dried over anhydrous sodium carbonate, concentrated under reduced pressure and purified chromatographically. This gives 4-[5-bromo-4-(2-phenylethyl)-1,3-thiazol-2-yl]piperidine (127 mg).

Aufarbeitung

  1. customThe aqueous phase is separated off
  2. extractionextracted with ethyl acetate
  3. dry with materialThe combined organic phases are dried over anhydrous sodium carbonate
  4. concentrationconcentrated under reduced pressure
  5. custompurified chromatographically

Quellen und Nachweise

ORD-Eintrag
ord-4d4c8d0847f74031b15aa5dc3076e71e
Quelldatensatz
uspto-grants-2011_05
Patentnummer
US07943774B2

Notizen zur Reaktion

Wird geladen…